Orthocell

23/02/2026

Meet Orthocell today at the 2026 AOA VIctoria Meeting in Lorne.

Today, we are attending the 2026 Australian Orthopaedic Association Victorian Branch Meeting, in Lorne.

Our dedicated team are here to discuss our cell therapies including OrthoACI™, an autologous chondrocyte implantation technology designed for the treatment of articular cartilage defects, and Remplir™, our collagen nerve wrap used in the repair of peripheral nerve injuries.

We’d love to speak to orthopaedic surgeons and healthcare professionals seeking to explore evolving biological treatment approaches. Come and learn more about our innovative nerve, tendon and bone repair devices.

We look forward to meeting you.

$OCC

20/02/2026

Meet Hamish Thrum and Trevor Turnull from Orthocell today or tomorrow at the 2026 Australian Orthopaedic Association, Victorian Branch Meeting in Lorne.

Our dedicated team is here to discuss our cell therapies, including OrthoACI™, an autologous chondrocyte implantation technology for the treatment of articular cartilage defects, and Remplir™, our collagen nerve wrap used for the repair of peripheral nerve injuries.

We’d love to speak with orthopaedic surgeons and healthcare professionals who are exploring evolving biological treatment approaches. Learn more about our innovative nerve, tendon, and bone repair devices.

We look forward to meeting you.

$OCC

18/02/2026

Orthocell will be at the ACFAS Conference | Las Vegas | 23-27 Feb.

The Orthocell team will be attending the 2026 American College of Foot and Ankle Surgeons Annual Scientific Conference in Las Vegas, next week.

We look forward to connecting with foot and ankle surgeons to discuss Remplir™, our collagen nerve wrap designed to support peripheral nerve repair and protection.

Remplir™ is used in procedures involving nerve decompression, nerve protection, and the management of nerve-related pathology commonly encountered in foot and ankle surgery, including digital nerves, neuromas, and tarsal tunnel–related nerve irritation.

Visit us at Stand #1728 to learn more about surgical strategies aimed at supporting nerve healing and about our innovative solutions for nerve, tendon, and bone repair.

We look forward to seeing you there.

$OCC

18/02/2026

Orthocell is showcased in the just-released Medical Technology, Devices and Diagnostics Industry Capability Report, co-authored by the Medical Technology Association of Australia and Austrade.

It provides a comprehensive overview of Australia’s MedTech strengths and global competitiveness.

Read the full report here: https://mtaa.org.au/medical-technology-devices-and-diagnostics-industry-capability-report

18/02/2026

Orthocell has received a Research and Development (R&D) Tax Incentive refund of A$3.0 million for the financial year ended 30 June 2025.

The R&D Tax Incentive is an Australian Government program to support Australian companies to undertake R&D activities in Australia, under which eligible companies can receive cash rebates of up to 48.5% of eligible expenditure on R&D activities.

Orthocell CEO and MD, Paul Anderson, said,

“Receipt of our R&D tax refund of $3.0 million is a valuable non-dilutive enhancement to our cash position. This Australian Federal Government program should be applauded, as it provides meaningful economic incentives to drive investment in R&D. Our flagship nerve repair product, Remplir, which is now being commercialised throughout the Americas and Asia Pacific, is a tangible example of a product that has benefited from this program.

“We’re in a very strong position to continue to drive the commercialisation of Remplir for the benefit of our shareholders with $49.6 million in cash, no debt and no royalties payable.”

🔗 Read today’s ASX release: https://bit.ly/3OnRa0S

$OCC &D

17/02/2026

Orthocell congratulates Marine biomedical on achieving a significant regulatory milestone with on the submission of its 510(k) application to the U.S. Food and Drug Administration (FDA) for PearlBone™.

PearlBone™ is a next-generation, marine-derived bone graft substitute developed from sustainably sourced pearl shell and designed to support bone repair and regeneration across orthopaedic, trauma and reconstructive procedures.

As announced in January, Orthocell has increased its equity interest in Marine Biomedical to 11.7% and secured first right of refusal over global distribution rights for PearlBone™ and future bone repair products.

This milestone aligns with Orthocell’s broader regenerative medicine strategy, complementing our established nerve and tendon repair technologies with advanced bone repair solutions.

We look forward to further updates from Marine Biomedical as the regulatory review progresses.

Marine Biomedical Submits 510(k) Application to the U.S. FDA for PearlBone™ We’re thrilled to share that Marine Biomedical has submitted its 510(k) application to the U.S. Food and Drug Administration (FDA) for PearlBone™. This marks a significant regulatory milestone and reflects years of dis...

12/02/2026

We’re pleased to share that John Morri, our Director of Quality, has been appointed to the AusBiotech Manufacturing Advisory Group for 2026.

The Advisory Group plays an important role in guiding policy, advocacy, and industry engagement on issues central to Australia’s life sciences manufacturing sector, including sovereign capability, global competitiveness, and supply chain resilience. The Group’s terms of reference are to support deeper collaboration between industry, government, and international partners.

This appointment reflects Orthocell's ongoing commitment to strengthening advanced manufacturing capability and contributing to the broader life sciences ecosystem.

Congratulations to John Morri on this well-deserved appointment. We look forward to the impact of his contribution to the sector.

11/02/2026

Orthocell Celebrates the International Day of Women and Girls in Science.

♀️Today, February 11th, we proudly acknowledge the incredible women at Orthocell, both past, present and those yet to join us, whose expertise, curiosity, and dedication drive our science forward every day.

👩🏻‍🔬 From research and development to quality, manufacturing, clinical operations, and beyond, these talented scientists and professionals play a vital role in advancing regenerative medicine and improving patient outcomes.

🔬 Women have always been instrumental in shaping scientific progress, and their leadership is more important than ever as we continue to push the boundaries of innovation.

🧬 At Orthocell Ltd, we are fortunate to have a team of passionate women who bring diverse perspectives, rigorous thinking, and an unwavering commitment to excellence.

🧪 To all the women in science, at Orthocell Ltd and around the world, thank you for your contributions, your perseverance, and your impact. Your work not only transforms our industry but also inspires the next generation of scientists.

10/02/2026

Snowmass is in full swing, and Orthocell is at Stand #17 all week.

Stop by to connect with the team and discuss how Remplir™ is being applied in peripheral nerve repair in upper extremity surgery.

$OCC

04/02/2026

📍 Visit us at the 21st Upper Extremity Tutorial in Snowmass, Colorado | 8-12 Feb

Our team is attending the Hand Rehabilitation Foundation's Tutorial, focused on reconstructive surgery of the shoulder, elbow and wrist in Snowmass next week.

With its strong educational focus on complex upper extremity pathology, the meeting provides an important forum to discuss advances in peripheral nerve repair.

We’ll be available to answer your questions about Remplir™, our collagen nerve wrap designed to support improved nerve repair outcomes.

We look forward to seeing you there.

$OCC

03/02/2026

What’s On | Upcoming Events for OCC in Australia

The Orthocell team is looking forward to attending these upcoming events on the East Coast of Australia. If you’re attending, please drop by to learn more about our suite of Australian-made medical devices spanning nerve, tendon and bone repair.

AOA Lorne
🗓️ February 20-22
📍 Mantra, Lorne, Victoria

At AOA Lorne our team will be on hand to discuss Autologous Chondrocyte Implantation (OrthoACI™) our cartilage repair product for the treatment of articular cartilage defects in the knee and ankle.

2026 AHSS Annual Scientific Meeting
🗓️ March 11-14
📍 Sofitel Melbourne on Collins, Melbourne, Victoria

Learn how Remplir is being used around the world for peripheral nerve repair, with a focus on surgical handling, early clinical experience and the growing evidence base in hand and upper limb surgery.

$OCC

02/02/2026

📺 Investor Webinar Replay

Earlier today Orthocell Chair, John Van Der Wielen, CEO and MD, Paul Anderson, and Independent Director, Dr Ravi Thadani provided investors with an important operational update on the US roll out of Remplir™.

In case you missed it, here’s the replay: https://youtu.be/YJZzfvvEKKs

$OCC

Orthocell Chair John Van Der Wielen, CEO and MD Paul Anderson, and Independent Director Dr Ravi Thadhani, give an update on the U.S. commercial rollout of Re...